Biopharmaceutical News and Research

RSS

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that data from its Phase I/II study of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published in Nature Medicine.

22 Jul 2015

PAREXEL introduces next generation Perceptive MyTrials Analytics solution

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today launched the next generation of its Perceptive MyTrials platform with advanced analytics capabilities. With the Perceptive MyTrials Analytics solution, clinical trial sponsors can now use a mobile-enabled, single entry-point to access predictive data analytics for multiple studies simultaneously.

From Parexel 21 Jul 2015

MGB Biopharma begins MGB-BP-3 Phase I clinical trial for treatment of Clostridium difficile infections

MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, to address the major global problem of antibiotic resistance today announces that the first group of healthy male volunteers have been dosed in a Phase I clinical trial assessing the safety and tolerability of an oral formulation of MGB-BP-3, for use in the treatment of Clostridium difficile infections.

21 Jul 2015

Dauntless, Aegis sign licensing agreement for Intravail drug delivery technology

Dauntless Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of specialty drugs and Aegis Therapeutics, LLC today announced a licensing agreement providing Dauntless' access to Aegis' Intravail drug delivery technology for an undisclosed oncology application and an option for three additional drugs.

21 Jul 2015

Patients' own genetically engineered immune cells show significant success against multiple myeloma

In recent years, immunotherapy has emerged as a promising treatment for certain cancers. Now this strategy, which uses patients' own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.

21 Jul 2015

XIAFLEX approved in Japan for treatment of patients with Dupuytren's contracture

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, announced that Asahi Kasei Pharma Corporation has received approval for its regulatory application to the Japanese Pharmaceutical and Medical Device Agency (PMDA) for XIAFLEX (collagenase clostridium histolyticum) for the treatment of patients with Dupuytren's contracture in Japan.

20 Jul 2015

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that ZEVALIN is now available at hospitals in Hong Kong to patients with indicated non-Hodgkin's lymphoma (NHL), including at Hong Kong Sanatorium & Hospital.

20 Jul 2015

Apogenix signs licensing agreement with CANbridge to commercialize APG101 in China, Macao and Hong Kong

Apogenix, a next generation immuno-oncology company, announced today that it has entered into an exclusive licensing agreement with CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, for the development and commercialization of lead immuno-oncology drug candidate APG101 in China, Macao, and Hong Kong.

15 Jul 2015

Agilent and BTI collaborate to address a critical need in biopharmaceutical industry

The collaboration will address a gap in analytical tests and standards applied for drugs based on glycoproteins, which now form the majority of approved biopharmaceutical drugs. Current analytical methods for characterizing glycans are time-consuming and difficult to deploy in commercial environments. They are also limited in their ability to detect and analyze minor glycan species.

15 Jul 2015

Four young scientists named recipients of Damon Runyon-Sohn Pediatric Cancer Research Fellowship Award

The Damon Runyon Cancer Research Foundation has named four outstanding young scientists as recipients of the prestigious Damon Runyon-Sohn Pediatric Cancer Research Fellowship Award, committing nearly $875,000 to help address a critical shortage of funding for pediatric cancer research.

10 Jul 2015

Galmed signs License Agreement for development of blood-based companion diagnostic tool

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases, announced today that it has entered into a Research, Option and License Agreement ("License Agreement") and a Share Purchase Agreement with One Way Liver Genomics S.L., for the development of a non-invasive, blood-based companion diagnostic tool.

8 Jul 2015

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.

8 Jul 2015

FDA accepts Adaptimmune’s IND application for MAGE-A10 T therapeutic candidate to combat NSCLC

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has accepted the Company's investigational new drug (IND) application for autologous genetically modified T-cells expressing enhanced T cell receptors specific for MAGE A10 (MAGE-A10 T) in patients with locally advanced or metastatic non-small cell lung cancer, and that the IND is now active.

2 Jul 2015

Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

Neuraltus Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on the development of groundbreaking drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), announced today that Robert G. Miller, M.D., Director of the Forbes Norris MDA/ALS Research Center at Sutter Health's California Pacific Medical Center in San Francisco, has been awarded a grant from The ALS Association for $1.5 million to help fund a Phase 2 clinical study of the company's investigational therapy for ALS, NP001.

1 Jul 2015

Genpact, UCB receive Aecus Innovation Award for collaboration in driving global business services

UCB, a multinational biopharmaceutical company, and Genpact, a global leader in designing, transforming, and running intelligent business operations, have received the Aecus Innovation Award in recognition of their close collaboration in driving transformation that achieved far-reaching operational efficiencies in UCB's global business services (GBS) finance organization.

1 Jul 2015

Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to its fully human monoclonal antibody Aerucin for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa.

30 Jun 2015

Two antibodies show early promise in preventing and treating MERS

As the South Korean epidemic of Middle East Respiratory Syndrome (MERS) continues unabated, researchers have raced to find treatments for the deadly virus, which has killed more than 400 people since it was first discovered three years ago in Saudi Arabia.

30 Jun 2015

Axovant Sciences accepts two presentations at Alzheimer's Association International Conference 2015

Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the acceptance of two presentations at the Alzheimer's Association International Conference 2015 (AAIC) being held in Washington, D.C. from July 18-23, 2015.

30 Jun 2015

Canada's first human gene therapy trial for choroideremia now underway at Royal Alexandra Hospital

Canada's first human gene therapy trial for eyes -- the replacement of a faulty gene with a healthy one -- is now underway at the Royal Alexandra Hospital to preserve and potentially restore vision for people with a genetic disorder that leaves them blind by middle age.

30 Jun 2015

TSRI-led study identifies new immune molecules that protect against Marburg virus

A new study led by scientists at The Scripps Research Institute identifies new immune molecules that protect against deadly Marburg virus, a relative of Ebola virus. The research provides ingredients needed to develop treatments for future Marburg outbreaks.

30 Jun 2015

Biopharmaceutical News and Research

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

PAREXEL introduces next generation Perceptive MyTrials Analytics solution

MGB Biopharma begins MGB-BP-3 Phase I clinical trial for treatment of Clostridium difficile infections

Dauntless, Aegis sign licensing agreement for Intravail drug delivery technology

Patients' own genetically engineered immune cells show significant success against multiple myeloma

XIAFLEX approved in Japan for treatment of patients with Dupuytren's contracture

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

Apogenix signs licensing agreement with CANbridge to commercialize APG101 in China, Macao and Hong Kong

Agilent and BTI collaborate to address a critical need in biopharmaceutical industry

Four young scientists named recipients of Damon Runyon-Sohn Pediatric Cancer Research Fellowship Award

Galmed signs License Agreement for development of blood-based companion diagnostic tool

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

FDA accepts Adaptimmune’s IND application for MAGE-A10 T therapeutic candidate to combat NSCLC

Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

Genpact, UCB receive Aecus Innovation Award for collaboration in driving global business services

Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Two antibodies show early promise in preventing and treating MERS

Axovant Sciences accepts two presentations at Alzheimer's Association International Conference 2015

Canada's first human gene therapy trial for choroideremia now underway at Royal Alexandra Hospital

TSRI-led study identifies new immune molecules that protect against Marburg virus

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News